Effect of Magnesium phosphoricum 6x andHomoeopathic constitutional medicines reducing pain in primary dysmenorrhoea - A prospective open-label double arm study - NIL

开始日期2028-11-09

申办/合作机构-

NCT04069572

/ SuspendedN/AIIT

Patterned Multichannel Vibratory Coordinated Reset (VCR) Stimulation for the Treatment of Chronic Pain

The purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions.

开始日期2026-09-01

申办/合作机构

Stanford University

CTRI/2024/07/070685

/ Not yet recruiting临床2期IIT

Efficacy of Dragon Tiger Fighting Needling Method on Primary Dysmenorrhea - A Randomized Controlled Trial - NIL

开始日期2025-07-28

申办/合作机构-

100 项与盆腔疼痛相关的临床结果

登录后查看更多信息

100 项与盆腔疼痛相关的转化医学

登录后查看更多信息

0 项与盆腔疼痛相关的专利（医药）

登录后查看更多信息

22,864

项与盆腔疼痛相关的文献（医药）

2025-12-31·Future Science OA

Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women

Article

作者: Tian, Qinjie ; Zhao, Xiaoyue ; Luo, Min

OBJECTIVETo investigate the therapeutic selection of abnormal uterine bleeding with ovulatory dysfunction (AUB-O) among Chinese women and analyze the impact of various factors.METHODSThis was a cross-sectional study involving 3527 patients with AUB-O diagnosed by local doctor between 14 and 55 years old. Questionnaire compiled according to the Chinese AUB-O treatment guidelines was used to collect the demographic and therapeutic information.RESULTSThe patients were divided into the juvenile group, the reproductive group, and the senior group. The results showed that irregular menstruation (37.6-46.3%), dysmenorrhea (29.9-44.4%), and heavy menstrual bleeding (16.7-32.2%) were the main symptoms in Chinese AUB-O patients. Most of the patients chose to seek help in the Department of General Gynecology (78.6-90.7%). Among the therapeutic options, combined oral contraceptives (COCs) met the treatment expectations with high acceptance among patients (36.6%-52.2%).CONCLUSIONThis study underscores the crucial need to fortify the endocrine diagnostic proficiency of doctors within the Department of General Gynecology. Furthermore, it also indicates that implementing clinical medication education programs for patients could facilitate their correct selection of appropriate therapeutic strategies for AUB-O.

2025-12-31·Annals of Medicine

Educating women to prevent and treat low back and pelvic girdle pain during and after pregnancy: a systematized narrative review

Review

作者: Gutke, Annelie ; de Baets, Liesbet ; Vesting, Sabine

PURPOSEThis review evaluated the effectiveness of patient education and information on low back pain (LBP) and pelvic girdle pain (PGP) in pregnant and postpartum women and evaluated their alignment with modern pain education principles rooted in the biopsychosocial model.METHODA systematized narrative review was performed, including a systematic search of three databases and reference screening from relevant systematic reviews. The methodological quality of the included randomized controlled trials (RCT) was evaluated using the PEDro scale.RESULTSEighteen studies, including nine RCTs with PEDro scores ranging from to 2-8, indicated that patient education during pregnancy can help reduce pain and related disability. Most studies did not differentiate between LBP and PGP, which limits the specificity and targeted approach of educational interventions. Education alone is less effective without accompanying active treatment. Current programs primarily emphasize biomechanics, covering anatomy and physical changes, but often neglect lifestyle factors, such as stress and sleep.CONCLUSIONAlthough patient education is important for managing pregnancy-related LBP and PGP, its effectiveness may be improved by tailoring programs to specific pain conditions and integrating a biopsychosocial perspective on pain.

2025-12-31·Journal of Obstetrics and Gynaecology

Brain functional connectivity changes on fMRI in patients with chronic pelvic pain treated with the Neuro Emotional Technique: a randomised controlled trial

Article

作者: Tobia, Anna ; Wintering, Nancy ; Zabrecky, George P. ; Ross, Reneita ; Mohamed, Feroze ; Navarreto, Emily ; Newberg, Andrew B. ; Monti, Daniel A. ; Vedaei, Faezeh ; Hriso, Chloe ; Raja, Rohit

BACKGROUNDChronic pelvic pain is a substantial clinical challenge that profoundly impacts quality of life for many women. The Neuro Emotional Technique (NET) is a novel mind-body intervention designed to attenuate emotional arousal of distressing thoughts and pain. This study evaluated functional connectivity changes in key areas of the brain in patients with chronic pelvic pain receiving the NET intervention. The goal was to assess whether the NET intervention was associated with functional connectivity (FC) changes in the brain related to reductions in emotional distress and pain, particularly in the limbic areas, sensory/pain regions, and cerebellum.METHODSThis is a prospectively designed study that included twenty-six patients with a diagnosis of chronic pelvic pain who were randomised to either the NET intervention or a waitlist control. To evaluate the primary outcome of neurophysiological effects, all participants received resting state functional blood oxygen level dependent (BOLD) magnetic resonance imaging (rs-fMRI) before and after the NET intervention or waitlist control period. Pain, mood, anxiety, and quality of life also were assessed.RESULTSCompared to the control group, the NET group demonstrated significant improvements in pain interference and pain intensity, and in emotional measures such anxiety and depression. Functional connectivity in the NET group compared to controls, was significantly decreased in the amygdala, cerebellum, and postcentral gyrus. There were also significant correlations between FC changes and changes in clinical measures.CONCLUSIONSThis study is an initial step towards describing a neurological signature of reducing emotional distress in women with chronic pelvic pain. Specifically, FC changes between the cerebellum and the amygdala and sensory areas appears to be associated with a reduction in pain and the effects of that pain. Future, larger clinical trials are warranted to further evaluate these mechanisms and NET as a potential therapeutic intervention in patients with chronic pelvic pain.

356

项与盆腔疼痛相关的新闻（医药）

2025-05-02

·PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

NHS patients will soon be able to access Theramex’s once-a-day endometriosis pill Yselty (linzagolix), following final draft guidance from the National Institute for Health and Care Excellence (NICE). The health technology assessment agency has recommended the at-home treatment be used to manage endometriosis symptoms in patients across England, Wales and Northern Ireland with a history of previous medical or surgical treatment for their endometriosis. It will be given with add-back hormone therapy, which involves using low-dose hormone replacement therapy to minimise or eliminate menopause-like symptoms and bone loss. Affecting approximately 1.5 million women in the UK, endometriosis occurs when tissue similar to the lining of the uterus grows elsewhere in the body. Patients can experience a range of symptoms, including dysmenorrhoea (painful cramping, usually in the lower abdomen), heavy bleeding and pelvic pain. Yselty is designed to block the hormones that contribute to endometriosis symptoms. The drug is expected to be available in the coming months and could benefit more than 1,000 patients every year, according to NHS England. NICE’s decision was supported by results from the EDELWEISS 3 study, in which Yselty used alongside add-back therapy demonstrated statistically significant reductions in both co-primary endpoints of non-menstrual pelvic pain and dysmenorrhea compared to placebo. Sue Mann, national clinical director in women’s health for NHS England, said: “This is welcome news for women with endometriosis who haven’t found relief from previous therapies or surgery – it’s another treatment option which will help women take control of their health and better manage the symptoms of this often painful and debilitating condition.” NICE’s final guidance on Yselty is set to be published on 25 June, after which the NHS must make the treatment available within 90 days. The announcement comes less than two months after NICE recommended Gideon Richter’s Ryeqo (relugolix, estradiol and norethisterone) as the first long-term daily pill for endometriosis. Commenting on the agency’s latest decision, Emma Cox, chief executive at Endometriosis UK said: “Historic lack of research into women’s health means those with endometriosis have far too few options for managing their sometimes debilitating pain and other symptoms of endometriosis. “It’s good to see companies investing in research, and NICE approving a new drug for endometriosis, offering more choice for those considering medical menopause to manage symptoms.”

临床结果临床3期上市批准

2025-04-25

·米内网

【获批】人福医药太猛了，170万喜提抗炎镇痛药首仿

精彩内容近日，人福医药公告称，其全资子公司武汉普克申报的3类仿制药萘普生钠软胶囊（0.22g）国内首家获批生产并视同过评，截至目前累计研发投入约170万元。该产品属于非甾体类抗炎药物，米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）抗炎抗风湿化药销售额超过220亿元。萘普生钠软胶囊为非甾体类抗炎药物，具有解热、镇痛、抗炎等作用，适用于缓解轻至中度疼痛，如关节痛、神经痛、肌肉痛、偏头痛、头痛、痛经、牙痛等。此前，萘普生钠有片剂、胶囊剂、颗粒剂、注射剂等多种剂型在销，此次人福医药的萘普生钠软胶囊剂国内首家获批，填补了该剂型的空白。值得一提的是，目前国内暂无企业布局该产品，人福医药有望在长时间内保持独家身份。米内网数据显示，2023年中国三大终端六大市场抗炎抗风湿化药销售额超过220亿元，同比增长约7%，2024上半年其销售额超过110亿元。从小类看，非甾体抗炎和抗风湿药占主导地位。近年来中国三大终端六大市场抗炎抗风湿化药销售情况（单位：万元）来源：米内网格局数据库2024上半年抗炎抗风湿化药TOP5品牌中，先声药业的1类新药艾拉莫德片居于榜首，较2023年提升1个位次；上药中西制药的硫酸羟氯喹片紧接其后，强生的布洛芬混悬液排位第三。从销售额增速看，江苏正大清江制药的盐酸氨基葡萄糖片大涨48.13%，先声药业的艾拉莫德片涨幅接近30%。2024上半年中国三大终端六大市场抗炎抗风湿化药TOP5品牌来源：米内网格局数据库今年以来，人福医药有8个品种获批生产并视同过评，包括5个神经系统药物、1个抗肿瘤和免疫调节剂、1个全身用抗感染药物及1个肌肉-骨骼系统药物。其中，萘普生钠软胶囊、盐酸他喷他多片为国内首仿+首家过评，琥珀酸地文拉法辛缓释片、马来酸咪达唑仑片国产第2家获批等。2025年以来人福医药获批上市的品种来源：米内网中国申报进度（MED）数据库此外，今年以来，人福医药还有5个品种以新注册分类申报上市/临床，分别为布瑞哌唑片（暂无首仿）、血管紧张素Ⅱ注射液（市场空白）、磷酸奥司他韦干混悬剂、戊酸雌二醇片及布洛芬软胶囊。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至4月25日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

2025-04-24

·米内网

【市场】亿级抗炎抗风湿药，葫芦娃获批了

精彩内容4月22日，国家药监局官网显示，海南葫芦娃药业的精氨酸布洛芬颗粒以仿制4类报产获批，视同过评。米内网数据显示，精氨酸布洛芬颗粒在2023年在中国三大终端六大市场（统计范围详见本文末）销售额超过1亿元，2024年上半年同比增长20.26%。今年以来，葫芦娃药业已有5款产品获批上市。2025年04月22日药品批准证明文件送达信息精氨酸布洛芬颗粒属于非甾体类抗炎药（NSAID），适用于牙痛、痛经、因创伤引起的疼痛（如运动性损伤）、关节和韧带痛、背痛、头痛、以及流感引起的发热等症状。近年中国三大终端六大市场精氨酸布洛芬颗粒销售情况（单位：万元）来源：米内网格局数据库精氨酸布洛芬颗粒在2023年中国三大终端六大市场销售额超过1亿元，2024年上半年同比增长20.26%。米内网数据显示，精氨酸布洛芬颗粒有9家企业拥有生产批文，海南葫芦娃药业、华润三九医药、安徽华辰制药等7家企业过评，海南赛立克药业、金鸿药业等8家企业均以仿制4类报产在审，获批后视同过评。葫芦娃药业今年以来产品获批情况来源：米内网中国申报进度（MED）数据库今年以来，葫芦娃药业新品捷报频传。精氨酸布洛芬颗粒、普瑞巴林口服溶液、骨化三醇软胶囊等5款产品获批上市，美阿沙坦钾片和艾司奥美拉唑镁肠溶干混悬剂报产在审，涵盖神经系统药物、消化系统及代谢药、呼吸系统用药等多个治疗大类。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准